REVIEW

Vitamin D and critical illness: what endocrinology can learn from intensive care and vice versa

K Amrein1,2, A Papinutti3, E Mathew3,4, G Vila5 and D Parekh6

1Thyroid Endocrinology Osteoporosis Institute Dobnig, Graz, Austria
2Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
3Department of General Surgery, Medical University of Graz, Graz, Austria
4Department of General Surgery, St. Elisabeth’s Hospital, Graz, Austria
5Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
6Clinician Scientist in Critical Care, Birmingham, Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK

Correspondence should be addressed to K Amrein: karin.amrein@medunigraz.at

Abstract

The prevalence of vitamin D deficiency in intensive care units ranges typically between 40 and 70%. There are many reasons for being or becoming deficient in the ICU. Hepatic, parathyroid and renal dysfunction additionally increases the risk for developing vitamin D deficiency. Moreover, therapeutic interventions like fluid resuscitation, dialysis, surgery, extracorporeal membrane oxygenation, cardiopulmonary bypass and plasma exchange may significantly reduce vitamin D levels. Many observational studies have consistently shown an association between low vitamin D levels and poor clinical outcomes in critically ill adults and children, including excess mortality and morbidity such as acute kidney injury, acute respiratory failure, duration of mechanical ventilation and sepsis. It is biologically plausible that vitamin D deficiency is an important and modifiable contributor to poor prognosis during and after critical illness. Although vitamin D supplementation is inexpensive, simple and has an excellent safety profile, testing for and treating vitamin D deficiency is currently not routinely performed. Overall, less than 800 patients have been included in RCTs worldwide, but the available data suggest that high-dose vitamin D supplementation could be beneficial. Two large RCTs in Europe and the United States, together aiming to recruit >5000 patients, have started in 2017, and will greatly improve our knowledge in this field. This review aims to summarize current knowledge in this interdisciplinary topic and give an outlook on its highly dynamic future.

A short history of vitamin D in critical care

Only 10 years ago, a potential link between acute illness and vitamin D, which is well known for its role in calcium and bone homeostasis, was regarded as quite absurd – how could this hormone be acutely relevant to the specialty of critical care? In fact, it now transpires that the high prevalence of vitamin D deficiency in critically ill adults and children, combined with the pleiotropic effects of vitamin D, could indeed be of great importance in this patient population.

The first relevant randomized controlled trial was published in 2003 by the Belgian endocrinology-anesthesiology visionary Greet van den Berge and her
team. In this trial, a ‘low’ dose of 200IU of vitamin D3 compared with a ‘high’ dose of 500IU over 10 days in 22 prolonged critically ill patients showed limited effects on inflammatory biomarkers (1). Although, in retrospect, the ‘high dose’ of vitamin D was quite low, this trial was ahead of its time and led the way revealing important findings of severe bone hyper-resorption and presence of vitamin D deficiency in the critically ill.

A few years of silence in the scientific community followed, but the topic rapidly regained attention after the publication of two studies in 2009: the report of high rates of vitamin D deficiency including some with undetectable levels among 42 Australian critically ill patients referred to the endocrinology department in a letter in the New England Journal of Medicine (2) and 100 children requiring ICU admission for respiratory infections by Canadian researchers (3). This was to be the beginning of subsequent years of research and debate with skeptics arguing that deficiency is purely a bystander and marker of illness severity. Despite this, the current evidence for replacement therapy is compelling, but there remain unanswered questions, including adequate dosing strategies, the effect of critical illness on vitamin D metabolism and the optimum target vitamin D level to provide clinical benefit in critical illness.

**Vitamin D status in critically ill patients**

Vitamin D deficiency is common in critical illness with prevalence between 40 and 70% (Table 1) (4, 5, 6, 7). In burn patients, the prevalence appears to be even higher.

### Table 1 Selected observational trials on the incidence of vitamin D deficiency in ICU patients.

<table>
<thead>
<tr>
<th>Author, Journal Year</th>
<th>Design</th>
<th>No of patients</th>
<th>Vitamin D deficiency definition</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Braun A, Critical Care Medicine, 2011 Boston, Massachusetts, USA (5)</td>
<td>Retrospective observational study Medical and surgical ICU patients</td>
<td>2399</td>
<td>Pre-admission 25(OH)D was categorized as deficiency in 25(OH)D (&lt;12 ng/mL) and insufficiency (12–24 ng/mL) and sufficiency (≥30 ng/mL)</td>
<td>Deficiency: 27% (637 patients) Insufficiency: 38% (918 patients) Sufficiency: 35% (844 patients)</td>
</tr>
<tr>
<td>Amrein K, Critical Care, 2014 Graz, Austria (13)</td>
<td>Retrospective observational study Medical and surgical ICU patients</td>
<td>655</td>
<td>25(OH)D was categorized as deficiency in 25(OH)D (&lt;20 ng/mL), insufficiency (20–30 ng/mL), normal (≥30 ng/mL)</td>
<td>Deficiency: 60% of patients Insufficiency: 26% of patients Normal level: 14% of patients Severe deficiency: 54% (138 patients) Moderate deficiency: 37% (96 patients) Mild deficiency: 7% (18 patients) Sufficiency: 1% (3 patients)</td>
</tr>
<tr>
<td>Matthews LR, American Journal of Surgery, 2012 Atlanta, USA (74)</td>
<td>Prospective observational study Surgical ICU patients</td>
<td>258</td>
<td>25(OH)D was categorized as severe deficiency in 25(OH)D (&lt;13 ng/mL), moderate deficiency (14–26 ng/mL) and mild deficiency (27–39 ng/mL), sufficiency (≥40 ng/mL)</td>
<td>Deficiency: 78% (340 patients) Insufficiency: 17% (74 patients) Normal level: 5% (23 patients)</td>
</tr>
<tr>
<td>Venkatram S, Critical Care, 2011 New York, USA (75)</td>
<td>Retrospective study Medical ICU patients</td>
<td>437</td>
<td>25(OH)D was categorized as deficiency in 25(OH)D (0–19 ng/dL), insufficiency (20–29.9 ng/dL) and normal levels (≥30 ng/mL)</td>
<td>Deficiency: 26% (50 patients) Insufficiency: 56% (109 patients) Normal level: 19% (37 patients)</td>
</tr>
<tr>
<td>Higgins DM, Journal of Parenteral and Enteral Nutrition, 2012 Ontario, Canada (76)</td>
<td>Prospective study Medical and surgical ICU patients</td>
<td>196</td>
<td>25(OH)D was categorized as deficiency in 25(OH)D (&lt;12 ng/mL), insufficiency (12–24 ng/mL) and normal levels (≥24 ng/mL)</td>
<td>Deficiency: 21% (21 patients) Insufficiency: 55% (55 patients) Normal level: 24% (24 patients)</td>
</tr>
<tr>
<td>Nair P, Intensive Care Medicine, 2015 Sydney, Australia (25)</td>
<td>Prospective multicenter cohort study ICU patients</td>
<td>100</td>
<td>25(OH)D was categorized as deficiency in 25(OH)D (&lt;10 ng/mL), insufficiency (10–20 ng/mL) and normal levels (≥20 ng/mL)</td>
<td></td>
</tr>
</tbody>
</table>

The dataset for this table is sourced from data compiled by the authors and provides a comprehensive overview of the incidence of vitamin D deficiency in ICU patients across various studies.
Many patients enter the ICU in a deficient state due to pre-existing malnutrition and disease. However, vitamin D metabolism is dysregulated in some critically ill patients with vitamin D levels rapidly falling after ICU admission (10, 11). The similarity between results in diverse geographical areas with variable UVB exposure suggests that the influence of individual chronic and/or acute disease on vitamin D deficiency is largely independent of sun exposure (12). A number of large observational studies from across the globe have confirmed that vitamin D deficiency (usually defined as 25(OH)D levels below 20 ng/mL) is frequent in adult and pediatric critical illness (5, 6, 13, 14, 15, 16). Vitamin D deficiency has been shown to be associated with sepsis, acute respiratory distress syndrome and acute kidney injury (17, 18, 19, 20) and three different meta-analyses confirm that patients with low vitamin D status have a higher ICU stay and increased morbidity and mortality (18, 21, 22). Recently, substantial metabolomic differences in pathways related to glutathione metabolism and glutamate metabolism were found in an observational study in vitamin D deficient compared to non-deficient ICU patients (separated by a cutoff of 15 ng/mL) (23).

In critical illness, there also is evidence of rapid falls in circulating 25(OH)D concentrations, potentially due to disrupted metabolism, fluid resuscitation, decreased synthesis of vitamin D-binding protein due to hepatic dysfunction, interstitial extravasation caused by increased vascular permeability, renal wasting of vitamin D, decreased renal conversion to 1,25(OH)D3 and increased tissue conversion of 25(OH)D3 to 1,25(OH)D3 (11, 24, 25, 26). The role of free/bioavailable vitamin D remains unclear although it is possible that although vitamin D binding protein (VDBP) and thus total D decreases, circulating free D may be maintained (27). In a post hoc analysis of the VITDAl-ICU trial, free/bioavailable vitamin D was not superior to total 25(OH)D in predicting mortality neither in the placebo nor in the intervention group (28). There is also evidence that critically ill patients with very low 25(OH)D concentrations have blunted responses to vitamin D replacement possibly due to conversion into alternate metabolites and epiforms (29).

**Biological rationale**

There is strong biological plausibility that supports a contributing role of vitamin D deficiency to poor outcomes, mediated by genomic and non-genomic effects (8). In the last decade, vitamin D has been implicated in

---

**Bone during and after critical illness**

Recently, bone health has been recognized as important for ICU survivors and the limited available data suggest impaired bone health and high fracture risk (38, 39, 40, 41). In addition to underlying disease, critical illness per se seems to be detrimental to musculoskeletal health in various ways: immobilization, inflammation, multiple endocrine alterations, hypercatabolism including muscle wasting, malnutrition and some drugs all have the potential to disturb the delicate balance between bone formation and resorption (42, 43). In a post hoc analysis of the VITDAl-ICU study, vitamin D3 did not have a significant effect on the increased levels of β-Crosslaps and osteocalcin during critical illness (44). Nevertheless, vitamin D is one of the cornerstones of osteoporosis therapy. Treatment of vitamin D deficiency with the aim to reach levels considered necessary for optimal bone health in other populations (above 20 ng/mL) (45, 46) may possibly be the only easily adoptable treatment to improve skeletal consequences of prolonged critical
illness besides other, more expensive, risky and/or time-consuming possibilities like antiresorptive treatment and physiotherapy. Hollander and Mechanick suggested the consideration of intravenous bisphosphonates which potently reduce bone resorption (47). However, a number of contraindications and potential side effects like hypocalcemia, renal impairment and atrial fibrillation need to be considered. In order to avoid frank hypocalcemia, vitamin D deficiency should always be treated before bisphosphonates are given. Interestingly, in a large retrospective analysis, patients pretreated with bisphosphonates had significantly better outcomes even though they were older; additional vitamin D seemed to have an additional beneficial effect (48). In summary, ICU survivors appear to be at high risk for excessive bone loss and fracture risk. Therefore, interventional studies with vitamin D and antiresorptive agents including denosumab and parenteral bisphosphonates are necessary in the near future.

**Effects of enterally administered vitamin D supplementation**

Van den Berghe et al. (1) tried to demonstrate that in critically ill patients an intravenous supplementation with 200 (low dose group) compared to 500 (high dose group) IU cholecalciferol results in elevated to normal vitamin D levels. Although higher levels of 25(OH)D were detected on days 2, 6 and 7 in the high-dose group compared to the low-dose group, they did not reach normal 25(OH)D levels.

Years later, Amrein et al. (49) initiated a randomized controlled pilot study with an ultra-high loading dose vitamin D (540,000IU) in ICU patients. In this trial, 25 patients were randomly assigned to vitamin D3 versus placebo. The results showed significantly elevated 1,25(OH)D levels in the intervention group and in 80%, normalized 25(OH)D levels were found. In consequence of these results, Amrein et al. (50) initiated the VITdAL-ICU trial, in which 475 ICU patients with vitamin D deficiency (<20 ng/mL) were randomly assigned to either high-dose vitamin D3 or placebo. The regimen of the high-dose group consisted of a single high-dose supplementation with 540,000 IU followed by a 90,000 IU monthly maintenance dose for five months. The 25(OH)D level in the high-dose group reached sufficiency (>30 ng/mL) in 52.2% of the patients after seven days.

Quraishi et al. (51) compared changes of 25(OH)D and cathelicidin levels in septic ICU patients. Thirty patients were randomly divided into three groups (each group consisting of 10 patients). The first group received 200,000IU cholecalciferol enterally, the second 400,000IU enterally and the third a placebo. Blood was drawn on days 1, 3, 5 and 7. Compared to baseline, the mean change in total 25(OH)D in the placebo group on day 5 was 3 (~3 to 8%), the 200,000IU cholecalciferol group
A lack of VDRs in the pulmonary epithelial barrier appeared to compromise its defense, leading to more severe lipopolysaccharide (LPS)-induced lung injury. Moreover, vitamin D treatment alleviated LPS-induced lung injury and preserved alveolar barrier function (35). Therefore, vitamin D may be a potential therapeutic strategy in acute lung injury and acute respiratory distress syndrome (ARDS). Vitamin D receptors are also present in all cells implicated in atherosclerosis. Those include endothelial cells, vascular smooth muscle cells and immune cells. It appears to regulate vascular cell growth, migration and differentiation; immune response modulation; cytokine expression; and inflammatory and fibrotic pathways. All of those mechanisms play a crucial role in different stages of the atherosclerotic plaque vulnerability and rupture (80).

Lung function

A lack of VDRs in the pulmonary epithelial barrier appeared to compromise its defense, leading to more severe lipopolysaccharide (LPS)-induced lung injury. Moreover, vitamin D treatment alleviated LPS-induced lung injury and preserved alveolar barrier function (35). Therefore, vitamin D may be a potential therapeutic strategy in acute lung injury and acute respiratory distress syndrome (ARDS).

Muscle function and metabolism

Some molecular mechanism studies suggest that vitamin D impacts muscle cell differentiation, intracellular calcium handling, and genomic activity. Some animal models have confirmed that vitamin D deficiency and congenital aberrations in the vitamin D endocrine system may result in muscle weakness (36, 81, 82). Limited available data in ICU survivors suggest impaired bone health and high fracture risk (38, 39, 40, 41, 83). 1,25(OH)(2)D(3) is known primarily as a regulator of calcium, but it also controls phosphate (re)absorption at the intestine and kidney. Mechanism of action involve 1,25(OH)2D3, FGF23 (fibroblast growth factor 23 – phosphaturic hormone produced in osteoblasts) and 1,25(OH)(2)D(3) via the PTH axis (84).

Bone

Limited available data in ICU survivors suggest impaired bone health and high fracture risk (38, 39, 40, 41, 83). 1,25(OH)(2)D(3) is known primarily as a regulator of calcium, but it also controls phosphate (re)absorption at the intestine and kidney. Mechanism of action involve 1,25(OH)2D3, FGF23 (fibroblast growth factor 23 – phosphaturic hormone produced in osteoblasts) and 1,25(OH)(2)D(3) via the PTH axis (84).

49 (30–82)% and the 400,000 IU group in 69 (55–106)% (P<0.001). The bioavailable 25(OH)D increased by 4 (–8 to 7)% 45 (40–70)% and 96 (58–136)% (P<0.01). Han et al. (52) administered cholecalciferol compared with placebo in a double-blind, randomized controlled pilot study in 30 patients. Nine mechanically ventilated ICU patients received 50,000 IU cholecalciferol on 5 days, 11 patients received 100,000 IU daily and 10 patients were given a placebo. At baseline, 13 patients (43%) had vitamin D deficiency (25(OH)D <20 ng/mL). The 50,000 IU and 100,000 IU regimens resulted in a significant increase in the average 25(OH)D plasma levels. On day 7, the values were 45.7 ± 19.6 ng/mL and 55.2 ± 14.4 ng/mL, respectively, compared to unchanged values in the placebo group (21 ± 11.2 ng/mL, P<0.001).

**Current vitamin D testing and supplementation in the ICU**

The most common laboratory test to assess vitamin D nutritional status is total 25-hydroxyvitamin D serum concentration. There are a number of methods for measuring 25-hydroxyvitamin D in serum or plasma, including enzyme immunoassay, radioimmunoassay, high-performance liquid chromatography (HPLC), liquid chromatography–mass spectrometry (LC/MS) and LC/MS/MS. Laboratory professionals are often confronted with challenges related to vitamin D testing, including controversy over optimal and target vitamin D concentrations, variable reference ranges across marketed assays and reference laboratories, lack of standardization of vitamin D assays and misordering of 1,25-dihydroxyvitamin D testing. Among possible markers, serum total 25(OH)D is currently considered to be the best marker of vitamin D status (53). Measurement of vitamin D concentration is currently not routine practice on ICU and there is currently no consensus on definition on vitamin D deficiency, in critical illness. The role of other metabolites including free/bioavailable vitamin D remains to be clarified. Generally, progress has been made in the last years in the harmonization of various assays. However, further standardization (e.g. the definition of vitamin D deficiency and measurement of other possible markers of vitamin D status) would be sensible (54).

---

Table 2  Mechanism of action on target organ systems that may influence critically ill patients.

<table>
<thead>
<tr>
<th>Target organs</th>
<th>Mechanism of action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immune system</strong></td>
<td>Vitamin D metabolites are acting as modulators of cells of the innate and adaptive system (30, 31, 34). Innate system: 1,25-dihydroxyvitamin D3 and 3 of its analogs induce expression of the human cathelicidin antimicrobial peptide (CAMP) gene and genes involved in autophagy and phagosome maturation all of which are involved in the intracellular destruction of pathogens; promotion of an anti-inflammatory response by inhibiting the maturation of DCs; Adaptive system: VitD induces anti-inflammatory responses through direct effects on T-cells (34, 77, 78).</td>
</tr>
<tr>
<td><strong>Cardiac function</strong></td>
<td>Vitamin D may play a role in atrial fibrilation prevention by negatively regulating the renin–angiotensin–aldosterone-system (RAAS), mediating calcium homeostasis, binding to vitamin D receptors (VDR) on cardiac myocytes and furthermore by having antioxidant properties that may reduce levels of reactive oxygen species (ROS) in the atria, which contribute to inflammation and proarrhythmic substrate formation (79). The exact mechanism of action unknown but the recent research on animal models suggest that calcitriol has been shown to have a key role in enabling the maturation and differentiation of ventricular myocytes isolated from neonatal rat hearts and could therefore potentially influence heart failure (37). Vitamin D receptors are also present in all cells implicated in atherosclerosis. Those include endothelial cells, vascular smooth muscle cells and immune cells. It appears to regulate vascular cell growth, migration and differentiation; immune response modulation; cytokine expression; and inflammatory and fibrotic pathways. All of those mechanisms play a crucial role in different stages of the atherosclerotic plaque vulnerability and rupture (80).</td>
</tr>
<tr>
<td><strong>Lung function</strong></td>
<td>A lack of VDRs in the pulmonary epithelial barrier appeared to compromise its defense, leading to more severe lipopolysaccharide (LPS)-induced lung injury. Moreover, vitamin D treatment alleviated LPS-induced lung injury and preserved alveolar barrier function (35). Therefore, vitamin D may be a potential therapeutic strategy in acute lung injury and acute respiratory distress syndrome (ARDS).</td>
</tr>
<tr>
<td><strong>Muscle function and metabolism</strong></td>
<td>Some molecular mechanism studies suggest that vitamin D impacts muscle cell differentiation, intracellular calcium handling, and genomic activity. Some animal models have confirmed that vitamin D deficiency and congenital aberrations in the vitamin D endocrine system may result in muscle weakness (36, 81, 82). Limited available data in ICU survivors suggest impaired bone health and high fracture risk (38, 39, 40, 41, 83). 1,25(OH)(2)D(3) is known primarily as a regulator of calcium, but it also controls phosphate (re)absorption at the intestine and kidney. Mechanism of action involve 1,25(OH)2D3, FGF23 (fibroblast growth factor 23 – phosphaturic hormone produced in osteoblasts) and 1,25(OH)(2)D(3) via the PTH axis (84).</td>
</tr>
<tr>
<td><strong>Bone</strong></td>
<td>Limited available data in ICU survivors suggest impaired bone health and high fracture risk (38, 39, 40, 41, 83). 1,25(OH)(2)D(3) is known primarily as a regulator of calcium, but it also controls phosphate (re)absorption at the intestine and kidney. Mechanism of action involve 1,25(OH)2D3, FGF23 (fibroblast growth factor 23 – phosphaturic hormone produced in osteoblasts) and 1,25(OH)(2)D(3) via the PTH axis (84).</td>
</tr>
</tbody>
</table>
In the general population, it is recommended that all healthy children and adults meet a daily minimum requirement of vitamin D – the Institute of Medicine (IOM) recommends 400–800IU of vitamin D3 (46). The Endocrine Society increased this dose to 1500–2000IU/day for individuals at risk of deficiency (45, 55). Current standard enteral nutrition formulas used in critical illness contain vitamin D2 or D3 (native vitamin D, half-life 2–3 weeks), but rarely more than 400IU in a daily regimen. Parenteral multivitamin preparations typically contain only 200 or 220IU of native vitamin D. In healthy individuals, such doses can improve vitamin D deficiency, but this requires months of treatment. In critical illness, the optimal native vitamin D dose remains unclear. Although no standard of care has been established, it appears logical that at least the recommended daily allowances for healthy individuals should be provided (400–600IU daily for children, 600–800IU for adults). The role for additional provision of active vitamin D (calcitriol or other metabolites) is even less clear, but certainly needs to be further tested. Active and native vitamin D metabolites are very different in half-life (several hours compared to a few weeks), therapeutic range (narrow vs broad) and costs (more expensive vs inexpensive) (56). There is however a biological rationale that active vitamin D on top of high-dose vitamin D3 could be of additional benefit. Besides patients with chronic preexisting renal dysfunction, many other ICU patients appear to be unable to sufficiently activate native vitamin D to its physiologically active form calcitriol (50). To date, no trial has looked at a combined vitamin D regimen.

Circulating 25(OH)D concentrations may fall rapidly during the initial phase of severe acute illness and its treatment. Therefore, the use of a loading mega-dose for rapid restoration of vitamin D levels followed by regular supplementation appears necessary in critical illness (57). Apart from intramuscular high-dose vitamin D formulations, no intravenous vitamin D mono-preparations are available at present.

**Side effects in critically ill patients**

Possible side effects after high dose supplementation include higher risk for fractures, falls and mild hypercalcemia. Symptoms are mostly related to the effects of hypercalcemia. Vitamin D intoxication can be caused by high intake (>50,000IU per day) and is typically linked to hypercalcemia and hyperphosphatemia. However, the intake of 10,000IU vitamin D3 per day for up to 5 months is considered safe (58).

In ICU patients, side effects are rare and no vitamin D intoxication has been reported. However, due to the complexity of the treatment and the underlying disease, recognition of adverse events in a critically ill population is difficult. Several studies in ICU patients using mainly oral cholecalciferol in doses ranging from 200IU to 540,000IU, reported very limited side effects (1, 50, 51, 59, 60). In the VITDAL-ICU study, Amrein et al. (50) found mild hypercalcemia in 1% of patients, all of which were asymptomatic. In this trial, overall no significant differences in calcium, phosphorus and renal parameters in either group were found. Vitamin D levels in the treatment group were well below the level considered acutely toxic (150ng/mL) (2). While outside of the ICU mega-doses are now obsolete because of increased fracture and fall risk (61), available evidence in critical illness from the VITdAL-ICU trial do not suggest increased risk for falls or fractures in these specific circumstances (50). Vitamin D toxicity has not been described in the ICU setting but may occur after prolonged intake of excessive doses (>10,000IU/day and 25(OH)D levels >200ng/mL) and, rarely, in individuals with mutations in CYP24A1 causing failure to metabolize 1,25-dihydroxyvitamin D (62, 63). Additional information on available vitamin D formulations is given in Table 3.

**What endocrinology can learn from intensive care and vice versa**

**Sample size and power of a study**

So far, many single vitamin D intervention trials have given disappointing results and many more, even relatively large trials including the recently completed VIDA and awaited VITAL trial are/will likely be negative (64). A great issue in these studies is that despite their relatively large size including thousands of individuals, they still are underpowered. Even more problematic, they have not exclusively included vitamin D-deficient subjects. It is not reasonable why patients with normal vitamin D levels are included in intervention trials; moreover, vitamin D should ideally not be given in the placebo group (65).

Recently, this concept was beautifully discussed in a German epidemiologic study showing that depending on the baseline risk of a population, the necessary sample size for a single trial to have adequate power increases sharply in low baseline risk (66). Therefore, the high prevalence of vitamin D deficiency and the inherently high morbidity and mortality in intensive care in a short time period increase the probability for an intervention trial to prove...
Table 3  Table summarising characteristics of available formulations of vitamin D, adjusted based on (30, 85).

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Native/active</th>
<th>Recommended daily dose</th>
<th>Onset/offset of action</th>
<th>Indications</th>
<th>Side effects</th>
<th>Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unhydroxylated, inactive form of vitamin D3</td>
<td>Native</td>
<td>400–4000 IU and up to 25,000–100,000 IU by hypoparathyroidismus (85)</td>
<td>Onset: 10–14 days</td>
<td>Vitamin D deficiency, osteoporosis therapy and prevention, hypoparathyroidism, prevention of rickets</td>
<td>Hypercalcemia (rare)</td>
<td>Inexpensive</td>
</tr>
<tr>
<td>Cholecalciferol</td>
<td></td>
<td></td>
<td>Offset: 14–75 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calciol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unhydroxylated, inactive form of vitamin D2</td>
<td>Native</td>
<td>400–4000 IU and up to 25,000–100,000 IU by hypoparathyroidismus</td>
<td>Onset: 10–14 days</td>
<td>Vitamin D deficiency, osteoporosis therapy and prevention, hypoparathyroidism, prevention of rickets</td>
<td>Hypercalcemia (rare)</td>
<td>Inexpensive</td>
</tr>
<tr>
<td>Ergocalciferol</td>
<td></td>
<td></td>
<td>Offset: 14–75 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin D2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydroxylated, active form of vitamin D 1,25(OH)2D</td>
<td>Active</td>
<td>0.25–1.0 µg</td>
<td>Onset: 1–2 days</td>
<td>Secondary hyperparathyroidism in advanced CKD, hypoparathyroidism, pseudohypoparathyroidism, not in vitamin D deficiency</td>
<td>Hypercalcemia/ hyperophosphatemia is not uncommon (dose dependent), hypercalciuria, nephrocalcinosis</td>
<td>Expensive</td>
</tr>
<tr>
<td>Calcitriol</td>
<td></td>
<td></td>
<td>Offset: 2–3 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1,25-Dihydroxyvitamin D3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1,25-Dihydroxycholecalciferol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analog: alfacalcidol</td>
<td>Active</td>
<td>0.5–3.0 µg</td>
<td>Onset: 1–2 days</td>
<td>Secondary hyperparathyroidism in advanced CKD, hypoparathyroidism, pseudohypoparathyroidism, not in vitamin D deficiency</td>
<td></td>
<td>Very expensive</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Offset: 5–7 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other active vitamin D analogs:</td>
<td>Active</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paricalcitol, doxercalciferol (vitamin D2 analogs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Falecalcitriol, maxacalcitol (vitamin D3 analogs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
a beneficial effect of vitamin D. Therefore, we believe that currently, targeting high-risk groups and including exclusively patients with vitamin D deficiency will reduce necessary sample sizes and improve the likelihood of showing an effect.

**Megadoses**

To date, megadoses and long dosing intervals are considered obsolete. Besides higher risk of falls and/or fractures in multiple studies (61, 67), Martineau was also able to show a decreased efficacy of high bolus doses in the prevention of acute respiratory tract infections (68). This lack of effect appears biologically reasonable, as after a large dose, possibly vitamin D is catabolized more rapidly to inactive metabolites. Also, it is rarely necessary to increase vitamin D levels rapidly. However, in critical care, time is paramount, and vitamin D levels must be improved within days which is only possible with a megadose (57). Typical dosing regimens used in outpatients are ineffective in this short time period but a single, large vitamin D3 dose works within a few days (69). Therefore, the best approach in intensive care is probably a large loading dose followed by a regular daily or weekly maintenance dose. The optimal dosing regimen is likely also dependent on individual patient factors including gastrointestinal function, underlying disease, co-medication, renal/hepatic function, genetic factors, ethnicity and body weight. In critical care, it also makes sense to determine serial vitamin D levels to guide therapy in patients with prolonged ICU/hospital stay.

**Vitamin D intervention trials in critical illness**

In recent years, several vitamin D interventional trials with or without placebo groups including vitamin D-deficient individuals or all-comers have been completed (Table 4). Given the low chance of successful normalization of vitamin D status with the traditional daily vitamin D regimen (57), other supplementation strategies including mega-doses for initial loading have been used. Overall, there is substantial variation in these studies regarding treatment duration (single dose or up to 6 months), dose, route of administration (enteral, intramuscular or intravenous) and metabolite (native vitamin D: cholecalciferol, ergocalciferol, active vitamin D: calcitriol). With the exception of the VITdAL-ICU trial (n=475) (50), these studies have been small (n<70). In the VITdAL-ICU trial, there was a non-significant absolute risk reduction in 6-month all-cause mortality in the vitamin D group (placebo: 43% vs vitamin D3: 35%). The findings did achieve statistical significance in the subgroup with severe vitamin D deficiency at baseline (25(OH)D <12 ng/mL) corresponding to a number needed to treat of 6 (50). The primary endpoint, length of hospital stay, however, was not different between groups.

Recently, three independent groups published meta-analyses on the effect of vitamin D on the mortality of ICU patients (70, 71, 72). Because of the small number of additional patients besides the VITdAL-ICU trial, and the substantial heterogeneity between studies, these meta-analyses have added little additional information and maybe even caused confusion (73, 74). The conclusions drawn by the three groups of authors varied according to study selection; however, the fact that currently less than 800 adult patients have been included in published RCTs makes meta-analyses problematic at this stage. Furthermore, none of these trials specifically included critically ill patients with severe vitamin D deficiency, which is the only subgroup where a significant beneficial effect of vitamin D supplementation on mortality has been shown to date. Ironically, similar to other settings, vitamin D deficiency was not an inclusion criterion in some studies. Six trials are currently registered on clinicaltrials.gov examining the effect of vitamin D supplementation in critically ill patients with vitamin D deficiency. One is a phase 2 study in children (NCT02452762). Three trials involve small numbers of selected sub-groups of critically ill patients (e.g. acute kidney injury, NCT02962102, neuro-critical care, NCT02881957). A single-center study (n=430) in Saudi Arabia is examining the effect of a single high dose (400,000IU) of vitamin D3 in critically ill patients with severe deficiency (25(OH)D <12 ng/mL) with a primary outcome of hospital mortality (NCT02868827). The last two are large multi-center randomized placebo-controlled trials that both have started in 2017 (summarized in Table 5) and will hopefully conclusively answer the question if vitamin D replacement confers clinical benefit in critical illness.

**Vitamin D intervention before critical illness**

In specific circumstances including intensive chemotherapy in some hemato-oncologic diseases, cardiac and other elective surgical procedures, ICU stay is foreseeable. Thus, we believe that diagnosing and treating vitamin D deficiency (besides iron and other nutritional deficiencies) appears reasonable in this subgroup, but there are currently no data to support such an approach.
Table 4  Selected prospective randomized controlled trials on the effect of oral/enteral vitamin D in adult critically ill patients.

<table>
<thead>
<tr>
<th>Author, Journal, Year</th>
<th>Design</th>
<th>No of patients</th>
<th>Intervention</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Completed trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amrein K, Critical Care, 2011</td>
<td>RCT 25 ICU, mechanically ventilated</td>
<td>1 × 540,000 IU D₃, enteral vs placebo</td>
<td>Normalization of vitamin D levels in most patients, no adverse events; no difference in 28-days mortality or length of stay</td>
<td></td>
</tr>
<tr>
<td>Graz, Austria (49)</td>
<td>RCT 475 Medical ICU, 25OHD &lt;20ng/mL</td>
<td>1 × 540,000 IU D₃, enteral, then 5 × 90,000 IU D₃/month vs placebo</td>
<td>No difference in hospital length of stay, overall no significant mortality benefit, but large and significant mortality benefit in the predefined subgroup with severe vitamin D deficiency (25OHD) &lt;12</td>
<td></td>
</tr>
<tr>
<td>Amrein K, JAMA, 2014</td>
<td>RCT 3000 ICU, sepsis</td>
<td>1 × 200,000 IU D₃, enteral or 1 × 400,000 IU D₃ enteral vs placebo</td>
<td>Rapid correction of vitamin D deficiency, increase in LL-37 compared to the placebo group</td>
<td></td>
</tr>
<tr>
<td>Graz, Austria (50)</td>
<td>RCT 2500 Surgical ICU, stress-induced hyperglycemia</td>
<td>5 × 50,000 IU D₃, enteral or 5 × 100,000 IU D₃ enteral vs placebo</td>
<td>Shorter hospital stay, dose dependent increase of vitamin D levels and increased hCAP18 mRNA-expression compared to the placebo group</td>
<td></td>
</tr>
<tr>
<td>Quraishi S, Critical Care Medicine, 2015</td>
<td>RCT 30 ICU, sepsis</td>
<td>600,000 IU D3, IM vs placebo</td>
<td>25OHD levels increased significantly in the vitamin D group at day 7, fasting plasma adiponectin levels increased significantly in the vitamin D group, but not the placebo group</td>
<td></td>
</tr>
<tr>
<td>Boston, USA (51)</td>
<td>RCT 50 ICU, ventilator associated pneumonia</td>
<td>300,000 IU D3, IM vs placebo</td>
<td>PCT levels significantly lower in the vitamin D group compared to placebo group, no significant difference in SOFA score between groups, mortality rate of patients in the vitamin D group was significantly lower than in the placebo group</td>
<td></td>
</tr>
<tr>
<td>Han JE, Journal of Clinical and Translational Endocrinology, 2016, Nutrition, 2017</td>
<td>RCT 30 ICU, mechanically ventilated</td>
<td>25OHD &lt;20 ng/mL</td>
<td>No difference in hospital length of stay, overall no significant mortality benefit, but large and significant mortality benefit in the predefined subgroup with severe vitamin D deficiency (25OHD) &lt;12</td>
<td></td>
</tr>
<tr>
<td>Atlanta, USA (52)</td>
<td>RCT 30 Surgical ICU, stress-induced hyperglycemia</td>
<td>Normalization of vitamin D levels in most patients, no adverse events; no difference in 28-days mortality or length of stay</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alizadeh N, International Journal of Clinical Practice, 2016</td>
<td>RCT 50 ICU, mechanically ventilated</td>
<td>1 × 540,000 IU D₃ enteral vs placebo</td>
<td>No difference in hospital length of stay, overall no significant mortality benefit, but large and significant mortality benefit in the predefined subgroup with severe vitamin D deficiency (25OHD) &lt;12</td>
<td></td>
</tr>
<tr>
<td>Teheran, Iran (86)</td>
<td>RCT 46 ICU, ventilator associated pneumonia</td>
<td>600,000 IU D3, IM vs placebo</td>
<td>Rapid correction of vitamin D deficiency, increase in LL-37 compared to the placebo group</td>
<td></td>
</tr>
<tr>
<td>Miroliaee AE, Iranian Journal of Pharmaceutical Research, 2017</td>
<td>RCT 46 ICU, ventilator associated pneumonia</td>
<td>300,000 IU D3, IM vs placebo</td>
<td>Shorter hospital stay, dose dependent increase of vitamin D levels and increased hCAP18 mRNA-expression compared to the placebo group</td>
<td></td>
</tr>
<tr>
<td>Teheran, Iran (87)</td>
<td>RCT 46 ICU, ventilator associated pneumonia</td>
<td>600,000 IU D3, IM vs placebo</td>
<td>No difference in hospital length of stay, overall no significant mortality benefit, but large and significant mortality benefit in the predefined subgroup with severe vitamin D deficiency (25OHD) &lt;12</td>
<td></td>
</tr>
</tbody>
</table>

Table 5  Comparison between the VITDALIZE and the VIOLET trial, the two ongoing, large vitamin D3 intervention trials in acute illness.

<table>
<thead>
<tr>
<th>VITDALIZE (NCT03188796)</th>
<th>VIOLET (NCT03096314)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Where</td>
<td>US, multicenter</td>
</tr>
<tr>
<td>Design</td>
<td>Double-blind, placebo-controlled RCT</td>
</tr>
<tr>
<td>Sample size</td>
<td>2400 (one interim analysis at 1200)</td>
</tr>
<tr>
<td>Intervention</td>
<td>Loading dose of 540,000IU vitamin D₃ (orally, enteral) Daily dose of 4000IU vitamin D₃ (orally, enteral) up to day 90</td>
</tr>
<tr>
<td>Inclusion criteria</td>
<td>25OHD &lt;12 ng/mL</td>
</tr>
<tr>
<td>Primary endpoint</td>
<td>28-day-mortality (all-cause)</td>
</tr>
<tr>
<td>Recruitment started</td>
<td>October 2017</td>
</tr>
<tr>
<td>Current status</td>
<td>Recruiting, estimated completion date 2021–2022</td>
</tr>
<tr>
<td></td>
<td>25(OH)D &lt;20 ng/mL by point-of-care test</td>
</tr>
<tr>
<td></td>
<td>Acute risk factors for ARDS and mortality contributing directly to the need for ICU admission</td>
</tr>
<tr>
<td></td>
<td>90-day-mortality (all-cause)</td>
</tr>
<tr>
<td></td>
<td>April 2017</td>
</tr>
<tr>
<td></td>
<td>Stopped after first interim analysis (July 2018, ca 1400 patients)</td>
</tr>
</tbody>
</table>

Conclusion

Over the last decade, experimental, observational and clinical studies have highlighted the high prevalence of vitamin D deficiency, and its strong association with morbidity and mortality in critical illness. The scientific rationale as to why this may be the case is compelling. Supporters of vitamin D do not suggest it to be the panacea but this hormone plays an important pleiotropic role in the setting of critical illness and may support recovery from severe acute illness. We now have a better, albeit not complete understanding from clinical trials of the potential target vitamin D level and dosing strategies required for conferring benefit. Importantly, vitamin D could therefore be considered an effective and safe therapy for the prevention of severe acute illness.
testing and supplementation is readily available, safe and inexpensive and could be rapidly implemented into clinical practice if the on-going trials show benefit.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding
K A received speaker fees and unrestricted research grants from Fresenius Kabi.

References


17 Braun AB, Litonjua AA, Moromizato T, Gibbons FK, Giovannucci E & Christopher KB. Association of low serum 25-hydroxyvitamin D levels and acute kidney injury in the critically ill. Critical Care Medicine 2012 40 3170–3179. [https://doi.org/10.1097/CCM.0b013e318260c928]


27 De Pascale G & Quareshi SA. Vitamin D status in critically ill patients: the evidence is now bioavailable! Critical Care 2014 18 449. [https://doi.org/10.1186/cc13975]


.jchomb.2016.01.049)
30 Prietl B, Treiber G, Pieber TR & Amrein K. Vitamin D and immune
nutrients5072502)
31 Reijnmark M, Bislev LS, Cashman KD, Eriiksdottir G, Gaksh M,
health effects of vitamin D supplementation: a systematic review on
findings from meta-analyses summarizing trial data. PLoS ONE 2017
12 e0180512. (https://doi.org/10.1371/journal.pone.0180512)
32 Boullon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A,
Luderer HF, Lieben L, Mathieu C & Demay M. Vitamin D and human
health: lessons from vitamin D receptor null mice. Endocrine Reviews
33 Campos LT, Brentani H, Roela RA, Katayama ML, Lima L,
Romil CF, Milani C, Folgueira MA & Brentani MM. Differences in
transcriptional effects of TGFalpha,25 dihydroxyvitamin D3 on
fibroblasts associated to breast carcinomas and from paired normal
breast tissues. Journal of Steroid Biochemistry and Molecular Biology
2013 133 12–24. (https://doi.org/10.1016/j.jsbmb.2012.08.002)
34 Hewison M. Vitamin D and immune function: an overview.
Proceedings of the Nutrition Society 2012 71 50–61. (https://doi.org/
10.1017/S0029665111001650)
35 Dancer RC, Pardeh D, Lax S, D’Souza V, Zheng S, Bassford CR,
Park D, Barts DG, Mahida R, Turner AM, et al. Vitamin D deficiency
contributes directly to the acute respiratory distress syndrome (ARDS).
36 Girgis CM, Clifton-Bligh RJ, Hamrick MW, Holick MF & Gunton JE.
The roles of vitamin D in skeletal muscle: form, function, and
metabolism. Endocrine Reviews 2013 34 33–85. (https://doi.org/
10.1210/er.2012-1012)
37 Lugg ST, Howells PA & Thickett DR. Optimal vitamin D
supplementation levels for cardiovascular disease protection. Disease
38 Orford N, Cattigan C, Brennan SL, Kotowicz M, Pasco J & Cooper DJ.
The association between vitamin D in skeletal muscle: form, function,
and metabolism. Endocrine Reviews 2013 34 33–85. (https://doi.org/
10.1210/er.2012-1012)
39 Orford N, Cattigan C, Brennan SL, Cooper DJ & Kotowicz MA. The association
between vitamin D level and cardiovascular health: a one-year pilot randomized controlled trial. PLoS ONE 2017 12 e0180512. (https://doi.org/
10.1371/journal.pone.0180512)
40 Orford N, Cattigan C, Brennan SL, Cooper DJ & Kotowicz MA. The association
41 Orford NR, Lane SE, Bailey M, Pasco JA, Cattigan C, Elderkin T,
Brennan-Olsen SL, Bellomo R, Cooper DJ & Kotowicz MA. Changes in
Critical Care 2013 17 221. (https://doi.org/10.1186/cc12435)
Critical Care 2013 17 221. (https://doi.org/10.1186/cc12435)
44 Schipper H, van Essen GA, Smits J, Boer P, Verbeek DJ, van der Meulen J,
Leenen LH & Amrein K. Effect of vitamin D on bone turnover
markers in critical illness: post hoc analysis from the VITDAL-ICU
10.1007/s00198-017-4190-1)
45 Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA,
Heaney RP, Murad MH & Weaver CM. Evaluation, treatment, and
prevention of vitamin d deficiency: an Endocrine Society Clinical
2011 96 1911–1930. (https://doi.org/10.1210/jc.2011-03855)
46 Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK,
report on dietary reference intakes for calcium and vitamin D from
the Institute of Medicine: what clinicians need to know. Journal of
Clinical Endocrinology and Metabolism. 2011 96 53–58. (https://doi.org/
10.1210/jc.2010-2704)
47 Hollander JM & Mechanick JI. Bisphosphonates and metabolic
bone disease in the ICU. Current Opinion in Clinical Nutrition and
Metabolic Care 2009 12 190–195. (https://doi.org/10.1097/
MCO.0b013e3181e328d6)
48 Lee P, Ng C, Slattery A, Nair P, Eisman JA & Center JR. Preamendment
bisphosphonate and mortality in critically ill patients. Journal of
doi.org/10.1210/jc.2015-3467)
49 Amrein K, Souri H, Wang G, Holl A, Pieber TR, Smolle KH,
Stojakovic T, Schindl C & Dobnig H. Short-term effects of high-
dose oral vitamin D3 in critically ill vitamin D deficient patients: a
50 Amrein K, Schindl C, Holl A, Riell J, Christoffer KB, Pachler C,
Effect of high-dose vitamin D3 on hospital length of stay in critically
ill patients with vitamin D deficiency: the VITDAL-ICU randomized
jama.2013.13204)
51 Quraishi SA, De Pascale G, Needleman JS, Nakazawa H, Kaneki M,
Bajwa EK, Camargo CA Jr & Bhan I. Effect of cholecalciferol
supplementation on vitamin d status and calcidiolin levels in sepsis:
a randomized, placebo-controlled trial. Critical Care Medicine 2015 43
1928–1937. (https://doi.org/10.1097/CCM.0000000000001148)
52 Han JE, Jones JL, Tangpricha V, Brown MA, Brown LAS, Hao L,
ill patients with vitamin D deficiency: the VITDAL-ICU randomized
jama.2013.13204)
53 Holick MF. Vitamin D deficiency. New England Journal of Medicine
54 Sopemos CA, Hetjober AC, Billek D, Bolser J, Boullon R, Brannon
Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D. British Journal of Clinical Pharmacology 2018 [epub]. (https://doi.org/10.1111/bcp.13652)
939–941. (https://doi.org/10.1017/S1368980011000590)
56 Schindl C, Dobnig H, Quraishi SA, McNally JD & Amrein K. Native
and active vitamin D in intensive care: who and how we treat is
crucially important. American Journal of Respiratory and Critical
Care Medicine 2014 190 1193–1194. (https://doi.org/10.1164/
jcc.201407-1354L)
57 McNally JD. Vitamin D as a modifiable risk factor in critical
illness: questions and answers provided by observational studies.
jpeds.2013.12.002)
58 Vieth R. Vitamin D toxicity, policy, and science. Journal of Bone and
Mineral Research 2007 22 Supplement 2 V64–V68. (https://doi.org/
10.1359/jbmr.070521)
Vitamin D and critical illness

K Amrein et al. Vitamin D and critical illness

7:12 R315


